Development of NHAcGD2/NHAcGD3 conjugates of bacteriophage MX1 virus-like particles as anticancer vaccines-Reference-Cited by-同舟云学术

Development of NHAcGD2/NHAcGD3 conjugates of bacteriophage MX1 virus-like particles as anticancer vaccines

Published:2024 Issue:9 Volume:14 Page:6246-6252
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Zhao Qingyu¹^ORCID,Huang Xuefei²,Wu Xuanjun¹^ORCID

Affiliation:

1. National Glycoengineering Research Center and Shandong Key Laboratory of Carbohydrate Chemistry and Glycobiology, NMPA Key Laboratory for Quality Research and Evaluation of Carbohydrate-based Medicine, Shandong University, Qingdao, Shandong 266237, China

2. Departments of Chemistry and Biomedical Engineering, Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan 48824, USA

Abstract

As a novel class of VLP vaccine carrier, the bacteriophage MX1 virus-like particle (VLP) is used for the first time to construct MX1-NHAcGD2 and MX1-NHAcGD3 conjugates. These conjugates can be exciting leads for anticancer vaccines.

Funder

Natural Science Foundation of Shandong Province

National Natural Science Foundation of China

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/RA/D3RA08923A

Reference46 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Development of a novel sialic acid-conjugated camptothecin prodrug for enhanced cancer chemotherapy

3. Targeting DNA topoisomerase II in cancer chemotherapy

4. Opportunities and challenges of radiotherapy for treating cancer

5. Synthesis of sialic acid conjugates of the clinical near-infrared dye as next-generation theranostics for cancer phototherapy